AI Engines For more Details: Perplexity Kagi Labs You
Weight Management: Glucomannan, the main component of konjac flour, is a soluble fiber that absorbs water in the digestive tract, forming a gel-like substance. This can increase feelings of fullness and reduce appetite, potentially aiding in weight management by promoting satiety and reducing calorie intake.
Digestive Health: Konjac flour is rich in soluble fiber, which can promote digestive health by regulating bowel movements, preventing constipation, and supporting a healthy gut microbiota. It can also help maintain regularity and alleviate symptoms of irritable bowel syndrome (IBS).
Blood Sugar Control: Some studies suggest that glucomannan may help improve blood sugar control by slowing down the absorption of glucose in the intestines and reducing postprandial blood sugar levels. This effect could be beneficial for individuals with diabetes or those at risk of developing diabetes.
Cholesterol Reduction: Soluble fiber, such as glucomannan, has been shown to help lower LDL cholesterol levels by binding to bile acids in the digestive tract and promoting their excretion. By reducing cholesterol absorption, konjac flour may contribute to cardiovascular health and lower the risk of heart disease.
Potential Weight Loss: Due to its ability to promote satiety and reduce calorie intake, konjac flour has been investigated as a potential aid for weight loss. Some studies have shown that supplementation with glucomannan can lead to modest weight loss when combined with a calorie-restricted diet and regular exercise.
Blood Pressure Regulation: Glucomannan supplementation may have a modest effect on reducing blood pressure, particularly systolic blood pressure, in individuals with hypertension. This effect is thought to be mediated by improvements in cholesterol levels and overall cardiovascular health.
Management of Metabolic Syndrome: Metabolic syndrome is a cluster of conditions that increase the risk of heart disease, stroke, and type 2 diabetes. Glucomannan supplementation has been shown to improve several metabolic risk factors associated with metabolic syndrome, including obesity, high cholesterol, and insulin resistance.
Gastrointestinal Health: Konjac flour may have prebiotic effects, promoting the growth of beneficial bacteria in the gut and contributing to gastrointestinal health. By supporting a healthy gut microbiota, konjac flour may help prevent digestive disorders and improve overall well-being.
| Rank | Probiotic | Impact |
|---|
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| ADHD | 1.6 | 0.8 | 1 |
| Age-Related Macular Degeneration and Glaucoma | 0.5 | -0.5 | |
| Allergic Rhinitis (Hay Fever) | 1 | 0.2 | 4 |
| Allergies | 0.4 | 0.5 | -0.25 |
| Allergy to milk products | 0.8 | 0.8 | 0 |
| Alopecia (Hair Loss) | 0.5 | 0.6 | -0.2 |
| Alzheimer's disease | 1.9 | 1.2 | 0.58 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.7 | 0.7 | |
| Ankylosing spondylitis | 1.6 | 0.8 | 1 |
| Anorexia Nervosa | 1 | 0.8 | 0.25 |
| Antiphospholipid syndrome (APS) | 0.2 | 0.2 | |
| Asthma | 0.7 | 1 | -0.43 |
| Atrial fibrillation | 1.5 | 1.7 | -0.13 |
| Autism | 2.3 | 3.2 | -0.39 |
| Barrett esophagus cancer | 0.9 | 0.9 | |
| Bipolar Disorder | 1.5 | 1.5 | |
| Brain Trauma | 0.3 | 1.4 | -3.67 |
| Carcinoma | 1.5 | 1.5 | 0 |
| Celiac Disease | 0.7 | 2.1 | -2 |
| Cerebral Palsy | 0.5 | -0.5 | |
| Chronic Fatigue Syndrome | 1.6 | 1 | 0.6 |
| Chronic Kidney Disease | 1 | 1 | |
| Chronic Lyme | 0.5 | -0.5 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.6 | 0.8 | -0.33 |
| Chronic Urticaria (Hives) | 0.7 | -0.7 | |
| Coagulation / Micro clot triggering bacteria | 0.8 | 0.8 | |
| Colorectal Cancer | 2.3 | 1.1 | 1.09 |
| Constipation | 1.8 | 0.3 | 5 |
| COVID-19 | 4.1 | 5 | -0.22 |
| Crohn's Disease | 2.8 | 2.8 | 0 |
| cystic fibrosis | 0.5 | -0.5 | |
| deep vein thrombosis | 0.3 | 0.3 | |
| Depression | 3.1 | 3.4 | -0.1 |
| Eczema | 1.1 | 0.2 | 4.5 |
| Endometriosis | 1 | 1 | |
| Epilepsy | 1.9 | 2.3 | -0.21 |
| Fibromyalgia | 1.3 | 0.7 | 0.86 |
| Functional constipation / chronic idiopathic constipation | 3.3 | 1.8 | 0.83 |
| gallstone disease (gsd) | 0.5 | 0.5 | 0 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.9 | 0.9 | |
| Generalized anxiety disorder | 0.7 | -0.7 | |
| Gout | 0.3 | 0.3 | |
| Graves' disease | 1.8 | 0.3 | 5 |
| Halitosis | 0.5 | 0.5 | |
| Hashimoto's thyroiditis | 1 | 0.5 | 1 |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 1 | 1 | |
| hyperglycemia | 0.3 | 1.7 | -4.67 |
| Hyperlipidemia (High Blood Fats) | 0.5 | -0.5 | |
| hypertension (High Blood Pressure | 1 | 1.2 | -0.2 |
| Hypoxia | 1 | 0.2 | 4 |
| IgA nephropathy (IgAN) | 1.3 | -1.3 | |
| Inflammatory Bowel Disease | 0.7 | 1.5 | -1.14 |
| Insomnia | 0.8 | 1.6 | -1 |
| Intelligence | 0.2 | 0.3 | -0.5 |
| Intracranial aneurysms | 1 | 1 | |
| Irritable Bowel Syndrome | 1.3 | 2 | -0.54 |
| Liver Cirrhosis | 2.1 | 1.6 | 0.31 |
| Long COVID | 2.7 | 3.7 | -0.37 |
| Low bone mineral density | 0.5 | -0.5 | |
| Lung Cancer | 0.2 | 0.4 | -1 |
| ME/CFS with IBS | 0.5 | 0.5 | 0 |
| ME/CFS without IBS | 0.7 | -0.7 | |
| Menopause | 0.2 | 0.2 | 0 |
| Metabolic Syndrome | 2.9 | 2.9 | 0 |
| Mood Disorders | 3.6 | 3.4 | 0.06 |
| Multiple Sclerosis | 1.2 | 1.9 | -0.58 |
| Multiple system atrophy (MSA) | 0.2 | 0.4 | -1 |
| neuropsychiatric disorders (PANDAS, PANS) | 0.5 | 0.5 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 1.8 | -1.8 | |
| Obesity | 2.3 | 1.9 | 0.21 |
| obsessive-compulsive disorder | 2.2 | 0.5 | 3.4 |
| Osteoarthritis | 0.7 | 0.7 | |
| Osteoporosis | 0.8 | 1.8 | -1.25 |
| Parkinson's Disease | 1.3 | 0.4 | 2.25 |
| Polycystic ovary syndrome | 2.1 | 0.8 | 1.63 |
| Premenstrual dysphoric disorder | 0.6 | 0.5 | 0.2 |
| primary biliary cholangitis | 0.5 | -0.5 | |
| Psoriasis | 0.2 | 2 | -9 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 1.5 | 2.5 | -0.67 |
| Rosacea | 0.6 | 0.6 | |
| Schizophrenia | 1.9 | 0.8 | 1.37 |
| sensorineural hearing loss | 0.3 | 0.3 | |
| Sjögren syndrome | 1 | 2.3 | -1.3 |
| Sleep Apnea | 1.6 | -1.6 | |
| Stress / posttraumatic stress disorder | 1 | 0.7 | 0.43 |
| Systemic Lupus Erythematosus | 1.7 | 1.4 | 0.21 |
| Tic Disorder | 0.4 | 0.5 | -0.25 |
| Tourette syndrome | 0.5 | 0.5 | 0 |
| Type 1 Diabetes | 1.3 | 0.2 | 5.5 |
| Type 2 Diabetes | 3.1 | 3.1 | 0 |
| Ulcerative colitis | 0.5 | 2.8 | -4.6 |
| Unhealthy Ageing | 0.9 | 0.9 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.